Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

NCT04203056 is registered in ClinicalTrials.gov with University of California, Los Angeles as lead sponsor.

NCT NCT04203056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04203056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
Lead sponsor
University of California, Los Angeles
Phase
Phase 4
Overall status
Terminated
Start date
December 16, 2019
Completion date
October 1, 2022
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, depressive type, schizophrenia, schizophreniform disorder